FDA rejects Merck's insomnia drug

Mon Jul 1, 2013 8:24am EDT

Related Topics

(Reuters) - Merck & Co Inc said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.

In a complete response letter to the company, the FDA said the safety data of the drug do not support approval, and advised that lower doses of the medicine should be made available before an approval.

The efficacy of the drug, suvorexant, was established at doses of 10 mg to 40 mg in adults, the FDA said, adding that 10 mg should be the starting dose for most patients.

(Reporting by Esha Dey in Bangalore)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.